Scarica l'app Stockscreener
6.25
0.64%
0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and Financial Insights - GuruFocus
Relmada Therapeutics 2025 Annual Report: Clinical-Stage Drug Development, Regulatory Risks, and Strategic Overview - Minichart
Relmada Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Relmada Therapeutics Inc.'s 2025 Q4 Call: 12-Month Data Timing, Phase 3 Enrollment, and R&D Cost Signals Don’t Match - Bitget
Relmada (RLMD) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Relmada Therapeutics (NASDAQ:RLMD) Releases Quarterly Earnings Results, Misses Estimates By $0.15 EPS - MarketBeat
Earnings call transcript: Relmada Therapeutics Q4 2025 shows EPS miss, stock stable - Investing.com India
RLMD: NDV-01 phase II data show 76% 12-month CR and strong safety, supporting phase III launch - TradingView
Relmada Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
RLMD: NDV-01 achieved 76% 12-month CR in NMIBC; $160M financing secures operations through 2029 - TradingView
Relmada (RLMD) Q4 2025 Earnings Call Transcript - The Globe and Mail
RLMD: NDV-01 delivers high response rates in NMIBC, with Phase 3 trials and strong financial runway ahead - TradingView
RLMD: NDV-01 achieved durable, high response rates with favorable safety in high-risk NMIBC - TradingView
Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relmada Therapeutics 10-K: $0 Revenue, $(1.45) EPS on $(57.39)M Net Loss - TradingView
RELMADA THERAPEUTICS ($RLMD) Releases Q4 2025 Earnings - Quiver Quantitative
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Relmada (NASDAQ: RLMD) pivots to NDV-01 cancer drug and sepranolone - Stock Titan
RLMD: Strong NDV-01 clinical results and $160M financing support Phase 3 launch and extended cash runway - TradingView
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update - The Manila Times
BRIEF-Relmada Therapeutics Q4 EPS USD -0.27 - TradingView
Bladder cancer drug shows 76% response at 12 months as Relmada readies Phase 3 - Stock Titan
Lucid Capital Markets initiates coverage of Relmada Therapeutics (RLMD) with buy recommendation - MSN
Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors - TipRanks
Relmada’s Withdrawn BOOST Trial Resets Expectations for NDV-01 and RLMD - TipRanks
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Analysts’ Top Healthcare Picks: Gain Therapeutics (GANX), Relmada Therapeutics (RLMD) - The Globe and Mail
Short Interest in Relmada Therapeutics, Inc. (NASDAQ:RLMD) Drops By 24.8% - MarketBeat
Mizuho reiterates Relmada stock rating on positive cancer trial data By Investing.com - Investing.com Australia
Mizuho reiterates Relmada stock rating on positive cancer trial data - Investing.com
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' - StreetInsider
Relmada Therapeutics (RLMD) Projected to Post Earnings on Thursday - MarketBeat
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN
Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data - Yahoo Finance
RLMD stock surges 42% in a week: Here's what you should know - MSN
Relmada Therapeutics, Inc. announced that it has received $159.999996 million in funding from a group of investors - marketscreener.com
RLMD Stock Surges 42% in a Week: Here's What You Should Know - sharewise.com
RLMD Shares Jump 42% Over the Past Week: Key Information You Need - Bitget
Relmada reports 76% response rate for bladder cancer therapy - Investing.com Nigeria
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Biotech Relmada schedules March 19 call on Q4 2025 results - Stock Titan
Should I buy Relmada Therapeutics (RLMD) - Zacks Investment Research
Relmada Therapeutics secures $160M in PIPE financing - Investing.com Nigeria
2 Under-the-Radar Stocks to Buy and Hold - AOL.com
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference - 富途牛牛
Relmada Therapeutics (NASDAQ:RLMD) Shares Gap DownTime to Sell? - MarketBeat
Relmada Therapeutics at Leerink Global: Strategic Shift to Uro-Oncology By Investing.com - Investing.com Canada
A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement - Yahoo Finance
Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer - Indian Pharma Post
Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01 - TipRanks
Relmada reports 76% response rate for bladder cancer therapy By Investing.com - Investing.com Canada
Relmada Therapeutics secures $160M in PIPE financing By Investing.com - Investing.com Canada
Relmada Therapeutics (RLMD) Stock Jumps 31% on Breakthrough Bladder Cancer Data - MEXC
Relmada CEO and CFO head to Miami for Leerink fireside chat, investor meetings - Stock Titan
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 12-Month HighShould You Buy? - MarketBeat
Relmada Therapeutics Announces 76% 12-Month Complete Response Rate in Phase 2 NDV-01 Trial for High-Risk Non-Muscle Invasive Bladder Cancer - Minichart
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
Relmada Therapeutics shares jump 25% after promising bladder cancer trial results - MSN
Mizuho reiterates Relmada stock rating on bladder cancer trial data By Investing.com - Investing.com UK
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data - Intellectia AI
Relmada Therapeutics Gains Attention with Promising Bladder Cancer Asset - timothysykes.com
1.20%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):